Rational Application of First-Line EGFR-TKIs Combined with Antiangiogenic Inhibitors in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Table 4

Subsequent systemic treatments in the and TKI alone groups.

Study	group	TKI alone group
Rates of total subsequent systemic treatments () (%)
JO25567 [12]	64/75 (85.3%)	65/77 (84.4%)
Stinchcombe [20]	23/43 (53.5%)	21/45 (46.7%)
NEJ026 [13]	85/112 (75.9%)	93/112 (83%)
RELAY [15]	120/224 (53.6%)	156/225 (69.3%)
Pooled rates	67.9% (95% CI: 63.8–72%)	75.3% (95% CI: 71.4–79.1%)
Pooled RR	0.881 (95% CI: 0.808–0.960),
Rates of subsequent osimertinib treatment () (%)
Stinchcombe [20]	10/23 (43.5%)	13/21 (61.9%)
NEJ026 [13]	29/85 (34.1%)	28/93 (30.1%)
RELAY [15]	18/120 (15%)	35/156 (22.4%)
Pooled rates	22% (95% CI: 16.8–27.2%)	27.2% (95% CI: 22.1–32.4%)
Pooled RR	0.858 (95% CI: 0.642–1.146),
Rates of subsequent chemotherapy () (%)
JO25567 [12]	26/64 (40.6%)	20/65 (30.8%)
NEJ026 [13]	44/85 (51.8%)	57/93 (61.3%)
RELAY [15]	27/120 (22.5%)	40/156 (25.6%)
Pooled rates	34.8% (95% CI: 29.4–40.3%)	35.9% (95% CI: 30.8–40.9%)
Pooled RR	0.969 (95% CI: 0.79–1.189),

TKI: tyrosine kinase inhibitor; : angiogenic inhibitors combined with TKI.